Skip to main content
. 2020 Mar 11;18:121. doi: 10.1186/s12967-020-02285-0

Fig. 3.

Fig. 3

Baseline frequencies of CD8+PD-1+ lymphocytes (a) and CD8+PD-1+CD73+  lymphocytes (b) in patients groups based on clinical benefit to nivolumab treatment. Baseline frequencies of CD8+PD-1+CD73+ lymphocytes in 1st line treatment (c) and 2nd/3rd line treatment (d) patients subgroups based on clinical benefit to nivolumab therapy. CB clinical benefit, n = 39/100; NCB no-clinical benefit, n = 61/100. Statistical analysis was performed with Mann–Whitney test. Line indicates the median